COSIMATI, ANTONELLA
 Distribuzione geografica
Continente #
EU - Europa 214
NA - Nord America 208
AS - Asia 76
AF - Africa 2
OC - Oceania 1
Totale 501
Nazione #
US - Stati Uniti d'America 205
IT - Italia 152
SG - Singapore 35
IN - India 23
SE - Svezia 14
FI - Finlandia 9
DE - Germania 8
IR - Iran 8
FR - Francia 7
BG - Bulgaria 6
CN - Cina 5
NL - Olanda 5
GB - Regno Unito 4
BE - Belgio 3
CA - Canada 3
CH - Svizzera 2
TG - Togo 2
TW - Taiwan 2
GR - Grecia 1
IE - Irlanda 1
KG - Kirghizistan 1
MY - Malesia 1
NZ - Nuova Zelanda 1
PL - Polonia 1
RO - Romania 1
TR - Turchia 1
Totale 501
Città #
Rome 68
Fairfield 23
Woodbridge 23
Singapore 19
Ashburn 18
Milan 17
Seattle 12
Santa Clara 11
Chandler 10
Houston 10
Wilmington 10
Helsinki 9
Cambridge 8
Dearborn 6
Sofia 6
West Jordan 6
Ann Arbor 5
Cascina 4
Fonte Nuova 4
Gurugram 4
New York 4
Paris 4
Rotondi 4
Amsterdam 3
Beijing 3
Bengaluru 3
Boardman 3
Brussels 3
Pescara 3
Princeton 3
Boston 2
Castano Primo 2
Isfahan 2
Kottayam 2
Lomé 2
Naples 2
Orta di Atella 2
Palermo 2
Paola 2
Plano 2
Redwood City 2
Romainville 2
Taipei 2
Torino 2
Toronto 2
Zurich 2
Albano Laziale 1
Athens 1
Bad Bellingen 1
Bangalore 1
Bergamo 1
Bishkek 1
Bonndorf 1
Bremen 1
Chengdu 1
Chiswick 1
Cuttack 1
Dallas 1
Dottingen 1
Dublin 1
Falkenberg 1
Frankfurt am Main 1
Fremont 1
Hebei 1
Heddesbach 1
Hyderabad 1
Kilburn 1
Lawrence 1
Leigh-on-Sea 1
Los Angeles 1
Lower Hutt 1
Munich 1
Napoli 1
Ozzano dell'Emilia 1
Perugia 1
Prato 1
Pune 1
Sacramento 1
San Diego 1
San Genesio Ed Uniti 1
San Jose 1
Tehran 1
Winnipeg 1
Totale 375
Nome #
Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study 165
Carotid plaque detection improves the predictve value of CHA2DS2-VASc score in patients with non-valvular atrial fibrilation. the ARAPACIS study 150
Comparative Analysis of Regorafenib and Trifluridine/Tipiracil in Later-Line Refractory Metastatic Colorectal Cancer: A Real-Life Multicenter Retrospective Study 66
Sequential treatment with regorafenib and trifluridine/tipiracil in later-line refractory metastatic colorectal cancer: A real-world multicenter retrospective study 54
398P Effectiveness and safety of regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A real-world multicenter retrospective study with focus on sequential treatment 26
Quality of life and emotional distress in sarcoma patients diagnosed during COVID-19 pandemic: a supplementary analysis from the SarCorD study 20
Treatment settings and outcomes with Regorafenib and Trifluridine/Tipiracil at third-line treatment and beyond in metastatic colorectal cancer: a real-world multicenter retrospective study 18
Psoriasis induced by first‑line pembrolizumab in metastatic non‑small cell lung cancer: a case report 15
P-368 Efficacacy of trifluridine/tipiracil according to extended RAS evaluation: A multicenter retrospective analysis 12
Retrospective Correlation between First Drug Treatment Duration and Survival Outcomes in Sequential Treatment with Regorafenib and Trifluridine/Tipiracil in Refractory Metastatic Colorectal Cancer: A Real-World Subgroup Analysis 7
P-360 Efficacy of regorafenib according to extended RAS evaluation: A multicenter retrospective analysis 6
P-195 Influence of age on disease control rate of patients treated with regorafenib and trifluridine/tipiracil in refractory metastatic colorectal cancer: A multicenter retrospective real-world study 6
Reply to the letter entitled: Re: The first report on Covid-19 vaccine refusal by patients with cancer in Italy: Early data from a single-institute survey 6
Totale 551
Categoria #
all - tutte 2.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.014


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202061 0 0 0 2 6 11 11 7 9 10 5 0
2020/202171 7 0 0 3 3 3 0 5 5 38 3 4
2021/202228 0 0 2 1 6 1 0 2 6 0 6 4
2022/2023120 8 15 3 7 2 3 3 21 29 3 9 17
2023/2024159 8 13 16 16 23 15 8 17 4 28 2 9
2024/202549 7 28 14 0 0 0 0 0 0 0 0 0
Totale 551